Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： John,Gribben

第一单位： Barts Cancer Institute, Queen Mary University of London, United Kingdom.

作者： John,Gribben ^[1] ; M Lia,Palomba ^[2] ; Anik R,Patel ^[3] ; Myrna,Nahas ^[3] ; Sattva S,Neelapu ^[4]

作者单位： Barts Cancer Institute, Queen Mary University of London, United Kingdom. ^[1] Memorial Sloan Kettering Cancer Center, New York, NY. ^[2] Kite, A Gilead Company, Santa Monica, CA. ^[3] The University of Texas MD Anderson Cancer Center, Houston, TX. ^[4]

主题词人类(Humans);费用效益分析(Cost-Benefit Analysis);淋巴瘤, 滤泡性(Lymphoma, Follicular);风险调节(Risk Adjustment);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived)

DOI 10.1182/bloodadvances.2022009469

PMID 36661331

发布时间 2023-06-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2023年7卷11期

2494-2495页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma.

Blood advances

相似文献

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma.

Blood advances

相似文献

Blood advances

相关期刊

检索历史清除